相似文献
1
Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment.
J Clin Microbiol. 2011 Jun;49(6):2304-6. doi: 10.1128/JCM.00325-11. Epub 2011 Apr 13.
2
Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans.
Antimicrob Agents Chemother. 2008 Nov;52(11):4145-8. doi: 10.1128/AAC.00959-08. Epub 2008 Sep 15.
3
Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata.
PLoS Pathog. 2012;8(5):e1002718. doi: 10.1371/journal.ppat.1002718. Epub 2012 May 17.
4
Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.
Antimicrob Agents Chemother. 2008 Oct;52(10):3783-5. doi: 10.1128/AAC.00473-08. Epub 2008 Aug 1.
5
Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo.
Antimicrob Agents Chemother. 2012 Jan;56(1):208-17. doi: 10.1128/AAC.00683-11. Epub 2011 Oct 10.
6
Candida lusitaniae MICs to the echinocandins are elevated but FKS-mediated resistance is rare.
Diagn Microbiol Infect Dis. 2016 Jan;84(1):52-54. doi: 10.1016/j.diagmicrobio.2015.08.012. Epub 2015 Aug 28.
7
Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity.
J Antimicrob Chemother. 2010 May;65(5):842-52. doi: 10.1093/jac/dkq073. Epub 2010 Mar 16.
8
Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.
J Clin Microbiol. 2011 Jul;49(7):2516-21. doi: 10.1128/JCM.00201-11. Epub 2011 May 4.
9
Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris.
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.00238-18. Print 2018 Jun.
10
A Candida albicans strain with high MIC for caspofungin and no FKS1 mutations exhibits a high chitin content and mutations in two chitinase genes.
Med Mycol. 2011 Jul;49(5):467-74. doi: 10.3109/13693786.2010.538732. Epub 2010 Nov 26.
引用本文的文献
1
Unlocking the potential of Metschnikowia pulcherrima: a dive into the genomic and safety characterization of four plant-associated strains.
Appl Microbiol Biotechnol. 2025 May 29;109(1):128. doi: 10.1007/s00253-025-13515-0.
2
Riverine mycobiome dynamics: From South African tributaries to laboratory bioreactors.
Mycology. 2024 Jan 30;15(4):631-650. doi: 10.1080/21501203.2023.2278309. eCollection 2024.
3
MetaFunc: taxonomic and functional analyses of high throughput sequencing for microbiomes.
Gut Microbiome (Camb). 2023 Jan 12;4:e4. doi: 10.1017/gmb.2022.12. eCollection 2023.
4
Mrs4 loss of function in fungi during adaptation to the cystic fibrosis lung.
mBio. 2023 Aug 31;14(4):e0117123. doi: 10.1128/mbio.01171-23. Epub 2023 Jul 11.
5
Mrs4 loss of function in fungi during adaptation to the cystic fibrosis lung.
bioRxiv. 2023 Apr 6:2023.04.05.535776. doi: 10.1101/2023.04.05.535776.
6
: Biology, Pathogenicity, Virulence Factors, Diagnosis, and Treatment.
Infect Drug Resist. 2022 Aug 31;15:5121-5135. doi: 10.2147/IDR.S383785. eCollection 2022.
7
Echinocandins Susceptibility Patterns of 2,787 Yeast Isolates: Importance of the Thresholds for the Detection of FKS Mutations.
Antimicrob Agents Chemother. 2022 May 17;66(5):e0172521. doi: 10.1128/aac.01725-21. Epub 2022 Apr 12.
8
A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints.
J Fungi (Basel). 2022 Jan 30;8(2):141. doi: 10.3390/jof8020141.
9
Participation of the ABC Transporter in Azole Resistance of .
J Fungi (Basel). 2021 Sep 15;7(9):760. doi: 10.3390/jof7090760.
10
Balancing Positive and Negative Selection: Evolution of Candida lusitaniae .
mBio. 2021 Mar 30;12(2):e03328-20. doi: 10.1128/mBio.03328-20.
本文引用的文献
1
Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
Drug Resist Updat. 2011 Jun;14(3):164-76. doi: 10.1016/j.drup.2011.01.004. Epub 2011 Feb 24.
2
Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients.
Antimicrob Agents Chemother. 2011 Feb;55(2):532-8. doi: 10.1128/AAC.01128-10. Epub 2010 Nov 15.
3
Novel FKS mutations associated with echinocandin resistance in Candida species.
Antimicrob Agents Chemother. 2010 May;54(5):2225-7. doi: 10.1128/AAC.00998-09. Epub 2010 Feb 9.
4
Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?
Lancet Infect Dis. 2009 Dec;9(12):789-95. doi: 10.1016/S1473-3099(09)70265-8.
5
Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.
J Clin Microbiol. 2010 Jan;48(1):52-6. doi: 10.1128/JCM.01590-09. Epub 2009 Nov 18.
6
Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
Clin Infect Dis. 2009 Jun 15;48(12):1695-703. doi: 10.1086/599039.
7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.
Antimicrob Agents Chemother. 2009 Jul;53(7):2982-90. doi: 10.1128/AAC.00880-08. Epub 2009 May 4.
8
Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism.
PLoS Med. 2008 Nov 11;5(11):e219. doi: 10.1371/journal.pmed.0050219.
9
Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing.
Antimicrob Agents Chemother. 2008 Sep;52(9):3092-8. doi: 10.1128/AAC.00088-08. Epub 2008 Jun 30.
10
Detection of caspofungin resistance in Candida spp. by Etest.
J Clin Microbiol. 2008 Jul;46(7):2389-92. doi: 10.1128/JCM.00053-08. Epub 2008 Apr 30.
Zotero 插件